Medication info

Boryeong Pregabalin Capsule 75 mg

Prescription medicationOralExpired
Ingredient · strength
Pregabalin›75mg / 1 capsule
Manufacturer / importer
Boryeong Co., Ltd.
Appearance
A hard capsule with a light brown upper part and a white lower part, containing a white or light yellow powder.
Packaging
30 capsules/bottle, 100 capsules/bottle
Approval status
Expired

MFDS item code 202001270 · Approved 2020.02.21

This product's status changed to Expired on 2025.02.21. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Treatment of neuropathic pain and fibromyalgia; adjunctive treatment of partial-onset seizures
Who takes it
Adults · Children
Adult dose
This medication is administered orally as pregabalin, in 2 divided doses per day, with or without food. Since this medication is primarily excreted by the kidneys, the dosage should be adjusted in patients with impaired renal function. (See section ‘5. Patients with Renal Impairment’.) 1. Neuropathic Pain 1) Peripheral Neuropathic Pain Adults: This medication may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of each individual patient, the dose may be increased to 300 mg/day after 3 to 7 days. If necessary, it may thereafter be increased at 7-day intervals up to a maximum of 600 mg/day. 2) Central Neuropathic Pain Adults: This medication may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of each individual patient, the dose may be increased to 300 mg/day after 1 week. After an additional 1 week, it may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, a dose reduction may be considered. (See section ‘4. Discontinuation of Treatment’.) 2. Epilepsy Adults: This medication may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of each individual patient, the dose may be increased to 300 mg/day after 1 week. If necessary, it may thereafter be increased at 7-day intervals up to a maximum of 600 mg/day. 3. Fibromyalgia The recommended dose of this medication for fibromyalgia is 300 mg to 450 mg/day. The initial dose is 75 mg twice daily (150 mg/day), and based on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg/day). For patients who do not experience sufficient benefit at a dose of 300 mg/day, the dose may be increased within 1 week to 225 mg twice daily (450 mg/day). Clinical studies have also been conducted at a dose of 600 mg/day; however, there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg/day are not recommended. 4. Discontinuation of Treatment Based on current clinical experience, if treatment with this medication is discontinued, it should be tapered gradually over at least 1 week. 5. Patients with Renal Impairment After entering the systemic circulation, this medication is primarily excreted by the kidneys in unchanged form. Since the clearance of this medication is directly affected by creatinine clearance, dose reductions in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the formula below. This medication is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose according to renal function, a supplemental dose should be administered promptly after each 4-hour hemodialysis session. [Table 1]. Pregabalin Dosage Based on Renal Function Creatinine clearance (CLcr), (mL/min) Total daily dose of pregabalin a Administration regimen Initial dose (mg/day) Maximum dose (mg/day) ≥60: Initial dose 150 mg/day, maximum dose 600 mg/day, BID or TID ≥30 -<60: Initial dose 75 mg/day, maximum dose 300 mg/day, BID or TID ≥15 -<30: Initial dose 25-50 mg/day, maximum dose 150 mg/day, QD or BID <15: Initial dose 25 mg/day, maximum dose 75 mg/day, QD Supplemental dose after hemodialysis: Initial dose 25 mg, maximum dose 100 mg, single dose b TID = total daily dose administered in 3 divided doses BID = total daily dose administered in 2 divided doses QD = administered once daily a: The total daily dose (mg/day) should be administered in divided doses as specified under the administration regimen. b: The supplemental dose refers to a dose administered once in addition to the regular dose. 6. Patients with Hepatic Impairment No dosage adjustment is necessary in patients with hepatic impairment. 8. Older Adults (65 years of age and older) Dose reduction may be necessary in older adults with impaired renal function.
Child dose
Children under 12 years of age: Administration is not recommended because there are insufficient safety and efficacy data. Adolescent patients aged 12–17 years: Administration is not recommended because there are insufficient safety and efficacy data.

Ingredients

Manufacturer
Boryeong Co., Ltd.

Efficacy & effects

Treatment of neuropathic pain and fibromyalgia; adjunctive treatment of partial-onset seizures

  • Peripheral neuropathic pain
  • central neuropathic pain
  • epilepsy
  • secondary generalized symptoms
  • partial seizures
  • fibromyalgia.
View approved original text

This medication is used to treat peripheral and central neuropathic pain in adults. It is also used as an adjunctive treatment for partial seizures in patients with epilepsy, applicable whether or not there are secondary generalized symptoms. Additionally, it helps alleviate symptoms of fibromyalgia. Overall, this medication effectively supports management of various nerve-related disorders and pain.

How to take

Adult dose

This medication is administered orally as pregabalin, in 2 divided doses per day, with or without food. Since this medication is primarily excreted by the kidneys, the dosage should be adjusted in patients with impaired renal function. (See section ‘5. Patients with Renal Impairment’.) 1. Neuropathic Pain 1) Peripheral Neuropathic Pain Adults: This medication may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of each individual patient, the dose may be increased to 300 mg/day after 3 to 7 days. If necessary, it may thereafter be increased at 7-day intervals up to a maximum of 600 mg/day. 2) Central Neuropathic Pain Adults: This medication may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of each individual patient, the dose may be increased to 300 mg/day after 1 week. After an additional 1 week, it may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, a dose reduction may be considered. (See section ‘4. Discontinuation of Treatment’.) 2. Epilepsy Adults: This medication may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of each individual patient, the dose may be increased to 300 mg/day after 1 week. If necessary, it may thereafter be increased at 7-day intervals up to a maximum of 600 mg/day. 3. Fibromyalgia The recommended dose of this medication for fibromyalgia is 300 mg to 450 mg/day. The initial dose is 75 mg twice daily (150 mg/day), and based on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg/day). For patients who do not experience sufficient benefit at a dose of 300 mg/day, the dose may be increased within 1 week to 225 mg twice daily (450 mg/day). Clinical studies have also been conducted at a dose of 600 mg/day; however, there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg/day are not recommended. 4. Discontinuation of Treatment Based on current clinical experience, if treatment with this medication is discontinued, it should be tapered gradually over at least 1 week. 5. Patients with Renal Impairment After entering the systemic circulation, this medication is primarily excreted by the kidneys in unchanged form. Since the clearance of this medication is directly affected by creatinine clearance, dose reductions in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the formula below. This medication is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose according to renal function, a supplemental dose should be administered promptly after each 4-hour hemodialysis session. [Table 1]. Pregabalin Dosage Based on Renal Function Creatinine clearance (CLcr), (mL/min) Total daily dose of pregabalin a Administration regimen Initial dose (mg/day) Maximum dose (mg/day) ≥60: Initial dose 150 mg/day, maximum dose 600 mg/day, BID or TID ≥30 -<60: Initial dose 75 mg/day, maximum dose 300 mg/day, BID or TID ≥15 -<30: Initial dose 25-50 mg/day, maximum dose 150 mg/day, QD or BID <15: Initial dose 25 mg/day, maximum dose 75 mg/day, QD Supplemental dose after hemodialysis: Initial dose 25 mg, maximum dose 100 mg, single dose b TID = total daily dose administered in 3 divided doses BID = total daily dose administered in 2 divided doses QD = administered once daily a: The total daily dose (mg/day) should be administered in divided doses as specified under the administration regimen. b: The supplemental dose refers to a dose administered once in addition to the regular dose. 6. Patients with Hepatic Impairment No dosage adjustment is necessary in patients with hepatic impairment. 8. Older Adults (65 years of age and older) Dose reduction may be necessary in older adults with impaired renal function.

Child dose

Children under 12 years of age: Administration is not recommended because there are insufficient safety and efficacy data. Adolescent patients aged 12–17 years: Administration is not recommended because there are insufficient safety and efficacy data.

Precautions

This medication may increase the risk of suicidal thoughts or behaviors, so if any symptoms of depression or mood changes occur during treatment, you should immediately inform your healthcare provider. Patients who are allergic to any of the ingredients in this medication should not take it. Moreover, patients with genetically-based lactose intolerance should also avoid taking this medication. Diabetic patients may need to adjust the dosage of their blood sugar control medications due to weight gain. If symptoms of angioedema appear, the medication should be stopped immediately. Elderly patients should be cautious of the risk of falls due to dizziness or drowsiness, and they may experience vision changes such as blurred vision. If this medication is suddenly discontinued, withdrawal symptoms such as insomnia, headache, nausea, and anxiety may occur, so consultation with healthcare providers is recommended when stopping the medication. Due to the risk of drug abuse, patients with a history of drug abuse should take extra caution. Patients with impaired renal function may need to adjust the dosage of this medication. Patients with heart disease should use it cautiously, as there is an increased risk of central nervous system depression when taken with opioid analgesics. Patients with compromised respiratory function or elderly patients may be at risk for severe respiratory depression and should consult with their healthcare provider. In early pregnancy, there is a risk of congenital malformations in the fetus, so women who are pregnant or planning to become pregnant should discuss with their doctor before taking this medication. Lactating women should consider stopping breastfeeding or discontinuing the medication, as it may pass into breast milk. This medication can cause dizziness and drowsiness, so activities such as driving or operating dangerous machinery should be avoided after taking it. In case of overdose, symptoms such as confusion, drowsiness, depression may occur, and treatment such as hemodialysis may be necessary. Store this medication out of reach of children, and it is recommended not to transfer it to another container. If any unusual symptoms such as skin rash, fever, or facial swelling occur during treatment, the medication should be stopped immediately and the healthcare provider informed.

Side effects

  • Suicidal thoughts
  • suicidal behavior
  • depression
  • abnormal changes in mood and behavior
  • angioedema
  • facial swelling
  • perioral swelling
  • upper respiratory tract swelling
  • dizziness
  • drowsiness
Show 207 more
  • loss of consciousness
  • confusion
  • mental disorders
  • blurred vision
  • changes in vision
  • insomnia
  • headache
  • nausea
  • anxiety
  • diarrhea
  • influenza-like illness
  • restlessness
  • depression
  • suicidal thoughts
  • pain
  • seizures
  • hyperhidrosis
  • misuse
  • abuse
  • dependence
  • congestive heart failure
  • severe respiratory depression
  • rhinitis
  • neutropenia
  • increased appetite
  • decreased appetite
  • hypoglycemia
  • confusion
  • disorientation
  • irritability
  • feelings of well-being
  • decreased libido
  • depersonalization
  • sexual paroxysms
  • restlessness
  • anxiety
  • mood swings
  • emotional lows
  • emotional highs
  • difficulty finding appropriate terms
  • hallucinations
  • abnormal dreams
  • increased libido
  • panic attacks
  • lack of impulse control
  • apathy
  • dizziness
  • drowsiness
  • ataxia
  • motor coordination abnormalities
  • balance disorders
  • amnesia
  • attention deficits
  • memory deficits
  • tremors
  • dysarthria
  • sensory disturbances
  • sensory loss
  • sedation
  • hypersomnolence
  • cognitive impairment
  • nystagmus
  • speech disorders
  • tonic-clonic spasms
  • decreased reflexes
  • motor abnormalities
  • psychomotor agitation
  • positional dizziness
  • hypersensitivity
  • burning sensation
  • tremor at rest
  • syncope
  • confusion
  • decreased motor function
  • olfactory disturbances
  • loss of taste
  • writing difficulties
  • blurred vision
  • diplopia
  • indirect vision loss
  • visual disturbances
  • visual field loss
  • photophobia
  • dry eyes
  • eye swelling
  • decreased vision
  • eye pain
  • eye fatigue
  • increased tear production
  • ocular irritation
  • mydriasis
  • vibration sensation
  • changes in depth perception of vision
  • strabismus
  • visual brightness
  • dizziness
  • hyperacusis
  • first-degree AV block
  • tachycardia
  • sinus bradycardia
  • sinus tachycardia
  • sinus arrhythmia
  • hypotension
  • hypertension
  • flushing
  • facial flushing
  • peripheral coldness
  • dyspnea
  • epistaxis
  • cough
  • nasal congestion
  • rhinitis
  • snoring
  • pharyngeal tension
  • nasal dryness
  • respiratory depression
  • vomiting
  • abdominal distension
  • constipation
  • dry mouth
  • abdominal pain
  • hypersalivation
  • gastroesophageal reflux disease
  • decreased oral sensation
  • ascites
  • dysphagia
  • pancreatitis
  • sweating
  • papular eruption
  • urticaria
  • cold sweats
  • muscle spasms
  • arthralgia
  • back pain
  • limb pain
  • cervical spasms
  • joint swelling
  • myalgia
  • muscle cramps
  • neck pain
  • muscle rigidity
  • rhabdomyolysis
  • voiding disorders
  • urinary incontinence
  • decreased urine output
  • renal failure
  • erectile dysfunction
  • delayed ejaculation
  • sexual dysfunction
  • dysmenorrhea
  • amenorrhea
  • mastalgia
  • nipple discharge
  • gynecomastia
  • peripheral edema
  • edema
  • gait abnormalities
  • falls
  • feeling drunk
  • sensory disturbances
  • fatigue
  • chest tightness
  • generalized edema
  • pain
  • fever
  • chills
  • weakness
  • thirst
  • weight gain
  • increased alanine aminotransferase
  • increased serum creatine phosphokinase
  • increased aspartate aminotransferase
  • increased blood sugar levels
  • decreased platelet count
  • decreased serum potassium
  • weight loss
  • increased serum creatinine
  • decreased white blood cell count
  • hypersensitivity
  • allergic reactions
  • headache
  • keratitis
  • pulmonary edema
  • nausea
  • diarrhea
  • tongue swelling
  • itching
  • Stevens-Johnson syndrome
  • toxic epidermal necrolysis
  • urinary retention
  • gynecomastia
  • lethargy
  • delirium
  • paralysis
  • affective disorders
  • drowsiness
  • confused state
  • depression
  • agitation
  • restlessness
  • exacerbation of seizures
  • gastrointestinal disorders
  • tinnitus
  • sleep disorders
  • skin diseases
  • elevated BUN
  • blood in stool

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to prevent air or moisture ingress. It is advisable to keep it in a cool place between 15 to 30 degrees Celsius.

Appearance and packaging

Appearance

A hard capsule with a light brown upper part and a white lower part, containing a white or light yellow powder.

Package unit

30 capsules/bottle, 100 capsules/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.